Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **levodropropizine**, a peripherally acting non-opioid antitussive, and **pelargonium sidoides extract**, a herbal extract with immunomodulatory and possible antimicrobial properties, primarily intended for the symptomatic treatment of **cough** and upper respiratory tract infections. Levodropropizine acts by inhibiting sensory C-fibers in the airway to suppress the cough reflex without significant central nervous system depression. Pelargonium sidoides extract is derived from the roots of the South African plant *Pelargonium sidoides* and is shown to have effects against pathogens associated with respiratory infections, and promotes immune responses. The combination is under development for enhanced therapeutic effect in respiratory infections and cough, benefiting from both antitussive and immunomodulatory actions[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levodropropizine + pelargonium sidoides extract.